BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September

Day

• 1
• 2
• 3
• 4
• 5

• 

  FDA

  Offit Out at FDA Vaccine Advisory Committee After HHS Rebuff

  Paul Offit, longtime member of the FDA’s vaccine advisory committee and an outspoken critic of Health Secretary Robert F. Kennedy Jr., was recently informed by the Department of Health and Human Services that his services are no longer required.

  September 2, 2025

   · 

  3 min read

   · 

  Heather McKenzie
• 

  Obesity

  Lilly Ends Two Mid-Stage Trials for Second Oral Obesity Asset

  While Eli Lilly’s orforglipron is full speed ahead for a regulatory filing this year, the pharma is also pushing forward with one more Phase II study of naperiglipron, which uses the same scaffold as Pfizer’s failed obesity drugs danuglipron and lotiglipron.

  September 2, 2025

   · 

  2 min read

   · 

  Tristan Manalac
• Press Releases

  AMI Pharm’s AYP-101 Shows Promise in Phase 2 Trial, Signaling a Breakthrough in Nonsurgical Fat Reduction

  September 2, 2025

   · 

  2 min read
• Press Releases

  Zai Lab Announces Approval of TIVDAK® for Patients with Recurrent or Metastatic Cervical Cancer in Hong Kong

  September 2, 2025

   · 

  4 min read
• Press Releases

  Upstream Bio to Host Conference Call and Webcast to Report Top-Line Data from the Phase 2 VIBRANT Trial of Verekitug in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)

  September 2, 2025

   · 

  2 min read
• Press Releases

  Professor Sarfaraz K. Niazi Secures First-Ever FDA Acceptance to Waive Clinical Efficacy Studies for Monoclonal Antibody Biosimilars

  September 2, 2025

   · 

  4 min read
• Press Releases

  Idorsia furthers the science of sleep and insomnia at World Sleep 2025

  September 2, 2025

   · 

  5 min read
• Press Releases

  LOTTE BIOLOGICS establishes contract manufacturing partnership with a leading U.S. Biopharmaceutical Company

  September 2, 2025

   · 

  2 min read
• Press Releases

  CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML

  September 2, 2025

   · 

  5 min read
• Press Releases

  Coloplast A/S - Coloplast presents new 5-year strategy, Impact4

  September 2, 2025

   · 

  7 min read